A comparative study of the efficacy of combination therapy with oral omeprazole and low dose of systemic meglumine antimoniate versus the standard dose of systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis

Recruitment status No longer recruiting	Prospectively registered		
	Protocol		
Overall study status	Statistical analysis plan		
Completed	[X] Results		
Condition category Skip and Connective Tissue Diseases	[] Individual participant data		
	No longer recruiting Overall study status Completed		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Mohammad Ali Nilfroushzadeh

Contact details

Khoram Street Skin Diseases and Leishmaniasis Research Center Isfahan Iran 81876-98191 +98 (0)31 13373736 nilfroushzadeh@mui.ac.ir

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Study objectives

The effect of oral omeprazole and low dose systemic meglumine antimoniate (MA) is more than the standard dose of systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The research has been ethically approved by the Ethical committee of the Skin Diseases and Leishmaniasis Research Center (SDLRC) on 11/02/2003, reference number: 85318

Study design

Double-blind randomised study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cutaneous leishmaniasis

Interventions

Group 1 was treated with intramuscular 60 mg/kg/day glucantime (MA) and placebo for three weeks.

Group 2 was treated with intramuscular 30 mg/kg/day glucantime and 40 mg of the oral

omeprazole for three weeks.

Group 3 was treated with intramuscular 30 mg/kg/day glucantime and oral placebo for three weeks

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Omeprazole, meglumine antimoniate (glucantime)

Primary outcome measure

Healing rate during the course of treatment was more in the groups treated with standard dose glucantime and placebo and low dose glucantime and omeprazole than the group treated with low dose glucantime and placebo (P < 0.05).

Secondary outcome measures

Combination therapy with oral omeprazole and low dose of glucantime can be used as alternative treatment for leishmaniasis especially in patients with history of cardiac, renal, and hepatic disease.

Patients with cardiac diseases were excluded because of some cardiac effects of the glucantime. However, glucantime is not absolutely contraindicated in patients with cardiac diseases and it can be prescribed with ECG monitoring. The study showed that the use of omeprazole as adjuvant therapy will decrease the dose of glucantime for the treatment of cutaneous leishmaniasis and therefore possibly decrease the risk of cardiac events attributed to the use of full dose of glucantime.

Overall study start date

28/06/2004

Completion date

28/06/2005

Eligibility

Key inclusion criteria

All of the patients had positive smear for leishman body and have not received any topical or systemic therapy for leishmaniasis. The age of patients was between 7-70 years old.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

150

Key exclusion criteria

Patients who were pregnant or lactating and patients with history of cardiac, renal, hepatic diseases or patients with any contraindication for treatment were excluded.

Date of first enrolment

28/06/2004

Date of final enrolment

28/06/2005

Locations

Countries of recruitment

Iran

Study participating centre

Khoram Street

Isfahan Iran 81876-98191

Sponsor information

Organisation

Skin Diseases and Leishmaniasis Research Center (SDLRC) (Iran)

Sponsor details

Khoram Street Isfahan Iran 81876-98191 +98 (0)31 13373736 sdlrc@mui.ac.ir

Sponsor type

Research organisation

ROR

https://ror.org/04waqzz56

Funder(s)

Funder type

Research organisation

Funder Name

Skin Diseases and Leishmaniasis Research Centre (SDLRC) at the University of Iran (Iran)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2008		Yes	No